All News
Filter News
Found 4,294 articles
-
TriSalus Life Sciences’ Pressure-Enabled Drug Delivery (PEDD) Increases Penetration and Antitumor Activity of Anti-CEA CAR-T in Mouse Model of Liver Metastases
5/11/2019
A preclinical trial to be presented at the annual meeting of the American Association of Immunologists demonstrated that administering anti–carcinoembryonic antigen CAR-T to liver metastases using high delivery pressure in an animal model simulating TriSalus™ Life Sciences’ innovative Pressure-Enabled Drug Delivery™ significantly increased penetration and antitumor activity when compared with standard low-pressure delivery.
-
BerGenBio ASA: Results for the First Quarter 2019
5/8/2019
BerGenBio ASA selective AXL kinase inhibitors for multiple cancer indications, announces its results for the first quarter 2019.
-
Celgene Corporation and bluebird bio published interim data from CRB-401, their Phase I trial of bb2121, their CAR-T therapy in patients with relapsed and refractory multiple myeloma.
-
GT Biopharma (GTBP) to Broadcast Update on TriKE Initiatives for HIV and Oncology at University of Minnesota On May 7th; Dr. Jeff Miller And Dr. Timothy Schacker to Host Event
4/25/2019
GT Biopharma, Inc. announced it will broadcast an update to shareholders and press of its Tri-Specific Killer Engager HIV for infected cells and product candidate GTB-3550 developed for the treatment AML at the University of Minnesota.
-
Seattle Genetics Reports First Quarter 2019 Financial Results
4/25/2019
Seattle Genetics, Inc. reported financial results for the first quarter ended March 31, 2019.
-
Daiichi Sankyo Selects Lead Candidate Built on Zymeworks’ Azymetric™ Bispecific Platform
4/25/2019
One of three bispecific immuno-oncology therapeutics being developed under the two companies’ collaboration agreements
-
ADC Therapeutics, based in Lausanne, Switzerland, and Adagene, headquartered in Suzhou, China and San Francisco, announced a discovery collaboration and license deal.
-
ADC Therapeutics and Adagene Announce License Agreement
4/24/2019
ADC Therapeutics to develop next-generation masked antibody drug conjugates (ADCs), incorporating Adagene’s SAFEbody™ technology, with potential utility across multiple tumor types
-
GT Biopharma (GTBP) Announces the Elimination of HIV Infected Cells Using its Tri-Specific Killer Engagers (TriKEs) in Preclinical Testing at the University of Minnesota
4/24/2019
GT Biopharma, Inc announced its Tri-Specific Killer Engager can target HIV infected cells in University of Minnesota's preclinical testing.
-
Forbius Announces First Patient Dosed in Phase 2a EGFR-Overexpressing Triple Negative Breast Cancer (TNBC) Trial of AVID100, a Novel, Tumor-Specific Anti-EGFR ADC
4/22/2019
AVID100 is the most advanced, broadly active anti-EGFR ADC in clinical development, targeting both wild-type and mutant forms of EGFR
-
The Nomination Committee's Proposal for the Annual Shareholders' Meeting in Alligator Bioscience AB (publ)
4/17/2019
Alligator Bioscience, announces that the Nomination Committee in Alligator Bioscience has presented its proposal for the annual shareholders' meeting on May 9, 2019, regarding election and remuneration of the board.
-
Cortexyme Announces Phase 2/3 Clinical Trial Based on Transformational Understanding of Alzheimer’s Disease Now Open for Enrollment
4/16/2019
The GAIN Trial will assess whether a new investigational medicine targeting P. gingivalis bacteria can slow or halt progression of Alzheimer’s disease
-
BioAtla Subsidiary, Himalaya Therapeutics, Will Develop And Commercialize CAB Products In Greater China Market
4/16/2019
First Conditionally Active Biologics licensing participation in Greater China territory
-
WuXi Biologics and NBE-Therapeutics Announce Comprehensive ADC Development and Manufacturing Partnership
4/10/2019
NBE-Therapeutics develops next-generation iADC products with the aim to improve the outcome for cancer patients, as it continues to develop iADCs based on its proprietary technology platforms.
-
Synaffix Announces License Agreement Worth up to $125 Million with Leading Chinese ADC Developer, Shanghai Miracogen
4/10/2019
Synaffix B.V., a Dutch biotechnology company exclusively focused on continued advancement of its clinical-stage antibody-drug conjugate (ADC) technology for the development of best-in-class ADCs, announces that it has entered into a license agreement with Shanghai Miracogen Inc., a Chinese biotechnology company with a clinical-stage pipeline of ADCs.
-
GT Biopharma Receives Institutional Review Board Approval to Proceed With in Human FDA Phase 1 Clinical Trial
4/8/2019
GT Biopharma, Inc. announced today it has received authorization from the University of Minnesota's Institutional Review Board and Cancer Protocol Review Committee that it can proceed with its planned TriKE Phase 1 clinical trial.
-
Celltrion Partners with the Canadian Biotech Company, iProgen Biotech to Develop a Series of Novel ADCs
4/8/2019
The deal aims to co-develop up to 4 ADCs including a novel ADC (Antibody-drug conjugate) that targets breast cancers expressing low levels of HER2 using iProgen’s proprietary antibody drug delivery technology.
-
Sutro Biopharma to Present at the 18th Annual Needham Healthcare Conference
4/4/2019
Sutro Biopharma, Inc. announced that Bill Newell, Chief Executive Officer, will present at the 18th Annual Needham Healthcare Conference on Tuesday, April 9 at 4:50 p.m. ET at the Westin Grand Central Hotel in New York.
-
Dyne Therapeutics closed on a $50 million Series A round. The company was founded, seeded and incubated by Atlas Venture, who led the round, which was joined by Forbion and MPM Capital.
-
BerGenBio: Preclinical Data Presented at AACR Reinforces Bemcentinib's Potential to Reverse Tumour Immunosuppression and Therapy Resistance
4/2/2019
Extensive data in pre-clinical models of non-small cell lung cancer (NSCLC) and pancreatic cancer demonstrating AXL's role in reversing tumour-mediated immunosuppression and therapy resistance presented at AACR